The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Meridian Bioscience Inc

Nasdaq: VIVO
Last

(U.S.) $16.80

Today's change+0.12 +0.72%
Updated December 26 4:00 PM EST. Delayed by at least 15 minutes.
 

Meridian Bioscience Inc

Nasdaq: VIVO
Last

(U.S.) $16.80

Today's change+0.12 +0.72%
Updated December 26 4:00 PM EST. Delayed by at least 15 minutes.

Meridian Bioscience Inc up (U.S.)$0.12

Meridian Bioscience Inc closed up Friday by (U.S.)$0.12 or 0.72% to (U.S.)$16.80. Over the last five days, shares have lost 0.94% and are down 36.68% for the last year to date. This security has underperformed the S&P 500 by 49.20% during the last year.

Key company metrics

  • Open(U.S.) $16.76
  • Previous close(U.S.) $16.68
  • High(U.S.) $16.91
  • Low(U.S.) $16.70
  • Bid / Ask-- / --
  • YTD % change-36.68%
  • Volume202,353
  • Average volume (10-day)295,781
  • Average volume (1-month)268,385
  • Average volume (3-month)277,896
  • 52-week range(U.S.) $15.80 to (U.S.) $27.72
  • Beta1.36
  • Trailing P/E20.34×
  • P/E 1 year forward19.51×
  • Forward PEG1.82×
  • Indicated annual dividend(U.S.) $0.80
  • Dividend yield4.76%
  • Trailing EPS(U.S.) $0.83
Updated December 26 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+18.40%

Based on its net profit margin of 18.40%, Meridian Bioscience Inc is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.10%Sector:HealthcareIndustry:Medical Equipment, Supplies & Distribution
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2014Q3/2014Q2/2014Q1/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue47475045
Total other revenue--------
Total revenue47475045
Gross profit28293228
Total cost of revenue18181917
Total operating expense35343433
Selling / general / administrative13131314
Research & development3333
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)0------
Other operating expenses, total--------
Operating income12131612
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax12131611
Income after tax89107
Income tax, total4454
Net income89107
Total adjustments to net income--------
Net income before extra. items89107
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items89107
Inc. avail. to common incl. extra. items89107
Diluted net income89107
Dilution adjustment--0----
Diluted weighted average shares42424242
Diluted EPS excluding extraordinary itemsvalue per share0.200.210.240.18
Dividends per sharevalue per share0.200.200.200.19
Diluted normalized EPSvalue per share0.200.210.240.18